Dr. Martens (LON:DOCS) Shares Down 11.6% – Should You Sell?

Dr. Martens plc (LON:DOCS) dropped 11.6% on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.90. Approximately 9,032,986 shares were traded during mid-day trading, an increase of 342% from the average daily volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

Trending Headlines about Dr. Martens

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg Bank reaffirmed its “buy” rating on DOCS, which could provide some analyst support and limit downside from purely sentiment-driven selling. Digital Look London Stock Exchange
• Negative Sentiment: Management projects flat revenue for 2026 and says it is scaling back discounts to protect margins — a signal that underlying demand may be weak. Investors often penalize top‑line stagnation even if margin discipline improves, which helps explain the selloff and high trading volume today. Dr Martens projects flat 2026 revenue as it scales back discounts

Analyst Ratings Changes

A number of analysts recently commented on DOCS shares. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Trading Down 11.6%

The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The business’s fifty day moving average is GBX 76.53 and its 200-day moving average is GBX 83.47. The stock has a market capitalization of £646.63 million, a PE ratio of 39.35, a P/E/G ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last announced its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Transactions at Dr. Martens

In other Dr. Martens news, insider Robert Hanson purchased 96,000 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, for a total transaction of £75,840. Over the last three months, insiders have purchased 97,130 shares of company stock worth $7,673,816. 2.79% of the stock is currently owned by corporate insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.